Vical Inc (VICL) 1.19 $VICL
Vical Narrows Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 12:00PM CDT
Vical Inc. (VICL) reported a narrower-than-expected loss per share in the first quarter of 2014.
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
Global Oral Cavity (Mouth) Cancer Global Clinical Trials Review Report 2014
M2 - Thu May 01, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmqsjv/oral_cavity) has announced the addition of the "Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cavity (Mouth) Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Cavity (Mouth) Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - C. H. Boehringer Sohn AG & Co. KG - Vical Incorporated - Pfizer Inc. - Galera Therapeutics LLC - CEL-SCI Corporation - National Cancer Institute - Roswell Park Cancer Institute - The University of Chicago - The University of Texas M. D. Anderson Cancer Center - NCIC Clinical Trials Group - University of Washington - Radiation Therapy Oncology Group - Tata Memorial Hospital - University of Miami Sylvester Comprehensive Cancer Center - Fox Chase Cancer Center For more information visit http://www.researchandmarkets.com/research/lm...ral_cavity
Vical Reports First Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu May 01, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter of 2014 was $3.5 million, or $0.04 per share, compared with a net loss of $9.3 million, or $0.11 per share, for the first quarter of 2013. Revenues for the first quarter of 2014 were $2.4 million, compared with revenues of $1.6 million for the first quarter of 2013, reflecting higher payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus
Vical Announces News Release and Conference Call Schedule for First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 23, 5:35AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2014, before the opening of trading on Thursday, May 1, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, May 1. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Marrone Bio Innovations Hires VP of Technology Development
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has hired Amit Vasavada, Ph.D., as Vice President of Technology Development, a newly created position within the company. Dr. Vasavada brings 30 years of experience in industrial bioproducts, fermentation R&D and manufacturing, process engineering, and technology transfer to MBI. His broad commercial background includes positions with General Atomics, Vical Inc., Diversa Corporation, Monsanto (CP Kelco), and Chiron Corp.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 21, 5:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Vical to Present at the ROTH Capital Partners 26th Annual Growth Stock Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, March 12, at 8:30 a.m. PDT at the ROTH Capital Partners 26th Annual Growth Stock Conference (Newport Beach, California March 9 - 12). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34 Annual Cowen Health Care Conference (Boston, Massachusetts March 3 - 5).
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Hot Stock: Vical, Shares Gain 14.7% (VICL)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 14.7% to $1.56 on 1.6x average daily volume. Thus far today, Vical has traded 3.4 million shares, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (14.7% to the Dow's -0.2%) and outperformed the S&P 500 (14.7% to the S&P's -0.0%) during today's trading.
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
The Global Gene Therapy Industry Has the Potential to Become a Multi-Million Dollar Industry by the End of 2017 Says Latest Offering
M2 - Mon Feb 10, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j8sfvg/global_gene) has announced the addition of the "Global Gene Therapy Market Analysis" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market in spite of presenting few marketable products and being nascent in terms of revenue generation holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2017 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. According to the new research report, Global Gene Therapy Market Analysis, major focus has been made on the ongoing clinical trials for the development of innovative products. Majority trials are focused on oncology and they prove promising on global scale for US. In this context, the study provides a comprehensive overview of the various aspects of clinical trials in the gene therapy market such as phases, geographies, vector types etc. The report provides an in-depth and prudent analysis of the industry and research developments taking place at the global level. Primarily the market is presently dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments on gene therapy include cardiac conditions, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Companies Mentioned: - AnGes MG, Inc - Ark Therapeutics - Ceregene, Inc - Cobra Biologics - GenVec, Inc - Genzyme Corporation - Vical, Inc - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/j8...lobal_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Vical to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 07, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Thursday, February 13, at 3:30 p.m. ET at the 2014 Leerink Global Healthcare Conference (New York City, February 12 - 13).
Vical Announces News Release and Conference Call Schedule for 2013 Financial Results
GlobeNewswire - Wed Feb 05, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2013, before the opening of trading on Wednesday, February 12, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Wednesday, February 12. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
Vical Narrows Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 12:00PM CDT
Vical Inc. (VICL) reported a narrower-than-expected loss per share in the first quarter of 2014.
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma
PR Newswire - Tue May 06, 11:41AM CDT
The markets on Monday, May 05, 2014 ended on a higher note as the S&P 500 finished the session 0.19% higher at 1,884.66, and the NASDAQ Composite closed at 4,138.06, up 0.34%. The Dow Jones Industrial Average finished at 16,530.55, up 0.11%. During the session, the eight out of ten sectors ended in positive. During the session gains in the Utilities, Health Care, and Materials sectors positively impacted the broader market, while some retraction came in from Consumer Staples and Financials sectors. The S&P 500 Health Care Sector Index closed the day at 672.57, up 0.56%, with the index also advancing 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Cytokinetics Inc. (NASDAQ: CYTK), Vical Inc. (NASDAQ: VICL) and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free technical research on PDLI, CYTK, VICL and PPHM can be downloaded upon signing up at:
Global Oral Cavity (Mouth) Cancer Global Clinical Trials Review Report 2014
M2 - Thu May 01, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lmqsjv/oral_cavity) has announced the addition of the "Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014" provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cavity (Mouth) Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Oral Cavity (Mouth) Cancer. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - C. H. Boehringer Sohn AG & Co. KG - Vical Incorporated - Pfizer Inc. - Galera Therapeutics LLC - CEL-SCI Corporation - National Cancer Institute - Roswell Park Cancer Institute - The University of Chicago - The University of Texas M. D. Anderson Cancer Center - NCIC Clinical Trials Group - University of Washington - Radiation Therapy Oncology Group - Tata Memorial Hospital - University of Miami Sylvester Comprehensive Cancer Center - Fox Chase Cancer Center For more information visit http://www.researchandmarkets.com/research/lm...ral_cavity
Vical Reports First Quarter 2014 Financial Results and Progress in Key Development Programs
GlobeNewswire - Thu May 01, 5:30AM CDT
Vical Incorporated (Nasdaq:VICL) today reported financial results for the quarter ended March 31, 2014. The net loss for the first quarter of 2014 was $3.5 million, or $0.04 per share, compared with a net loss of $9.3 million, or $0.11 per share, for the first quarter of 2013. Revenues for the first quarter of 2014 were $2.4 million, compared with revenues of $1.6 million for the first quarter of 2013, reflecting higher payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
Global Herpes Simplex Infections Therapeutics Pipeline Review 2014 - Analysis of 30 Companies & 47 Drug Profiles
M2 - Mon Apr 28, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2zbrdd/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Vical Incorporated - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Nutra Pharma Corporation - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - Spider Biotech S.r.l. - Kala Pharmaceuticals, Inc. - Coridon Pty Ltd - Sanofi Pasteur SA - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - amenamevir - tenofovir - RPI-78M - RPI-MN - HSV-2 Vaccine - CEL-1000 - HSV Vaccine - HSV-2 Vaccine - C-31-G - MucoCept Platform - HSV-2 Px - NVC-727 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - GV-2207 - MB-66 - Small Molecule Targeting Fatty Acid Synthase for Infectious Disease - BA-368 - HSV-2 Vaccine - RKP-00156 - CEL-1000 - MAb hu2c - HSV Vaccine - Drug For Herpes Simplex Virus - Subunit Vaccine for Herpes Simplex Virus 2 - Small Molecules for Viral Infections - Small Molecules for Bacterial and Viral Infections For more information visit http://www.researchandmarkets.com/research/2z...es_simplex
Global Cytomegalovirus (HHV-5) Infections Therapeutics Pipeline Review 2014 - Analysis of 26 Companies & 57 Drug Profiles
M2 - Mon Apr 28, 4:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b58mx2/cytomegalovirus) has announced the addition of the "Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development - Vical Incorporated - GlaxoSmithKline plc - Genentech, Inc. - Merck & Co., Inc. - Novartis AG - Astellas Pharma Inc. - 4SC AG - Bionor Pharma ASA - Altor BioScience Corporation - Phoenix Biotechnology, Inc. - Cell Medica Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Microbiotix, Inc. - 4-Antibody AG - VBI Vaccines - AIMM Therapeutics B.V. - Trellis Bioscience, Inc. - Vakzine Projekt Management GmbH - Spider Biotech S.r.l. - INAGEN ApS - Applied Immune Technologies Ltd - Redbiotec AG - Kadmon Corporation, LLC - Humabs BioMed SA - BioApex, s.r.o. Drug Profiles - brincidofovir - ASP-0113 - Cytovir CMV - maribavir - TCN-202 - ASP-0113 - Donor-Derived CMV-pp65 Peptide-Specific T Cells - letermovir - RG-7667 - Multi-Virus Specific T Cells - CMV pp65 Specific T Cells - T-Cell Immunotherapy - CMV Streptacells - Autologous T-Cell Therapy - AVX-601 - HCMV Specific CTL - CMV Specific CTL - Cytomegalovirus Vaccine - CMV Specific T Cell Donor Lymphocyte - Multi-Virus Cytotoxic T Lymphocytes - Small Molecule 1 For Human Cytomegalovirus Infection - Small Molecule 2 For Human Cytomegalovirus Infection - CMV TCR-001 - CMV-MVA Triplex Vaccine - V-160 - CyMVectin - Antiviral TCR-Ck - Antiviral TCR-Ig - 4Ab-028 - VPM-2001 For more information visit http://www.researchandmarkets.com/research/b5...egalovirus
Vical Announces News Release and Conference Call Schedule for First Quarter 2014 Financial Results
GlobeNewswire - Wed Apr 23, 5:35AM CDT
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended March 31, 2014, before the opening of trading on Thursday, May 1, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, May 1. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on independent and partnered development programs in the conference call and webcast.
Global Therapeutic Vaccines Market 2014-2018 with Agenus, Bavarian Nordic A/S, Dendreon, GSK & Novartis International Dominating
M2 - Wed Apr 16, 5:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb45f5/global) has announced the addition of the "Global Therapeutic Vaccines Market 2014-2018" report to their offering. The Global Therapeutic Vaccines market to grow at a CAGR of 62.81 percent over the period 2013-2018. The increase in technological advances and improved understanding of immunology and immunotherapy has enabled the discovery of many biomarkers, thus aiding the development of therapy through the body's natural defense mechanism. Vaccines are usually thought of as biologics, which elicit an immune response to initiate a defense mechanism. This led to the development of therapeutic vaccines, which can induce the immune system to attack the targeted diseased tissue with greater bioavailability and specificity with minimal side effects. Various strategies have been developed to make therapeutic vaccines viable alternatives to the existing therapeutic approaches. Thus, improved understanding of immunology and immunotherapy is expected to boost the growth of the Global Therapeutic Vaccines market. According to the report, the incidence of cancers, infectious diseases, and physiological disorders is widespread owing to poor lifestyle, low immunity, and unhygienic conditions. As a result, the incidence of disorders such as Alzheimer's disease, Parkinson's disease, cancer, diabetes, and infectious diseases such as Hepatitis B, HIV/AIDS, and HPV is rising. The manifestation of these ailments is expected to increase due to a rise in aging population. The use of these vaccines to treat such ailments will be boosted by an increase in prevalence of these diseases and disorders, thus boosting the growth of the market. Further, the report states that the stringent government regulations could lead to delays in production and additional manufacturing costs. Vendors transfer the burden of the extra costs onto the end-users, making the adoption of the vaccines challenging. Key Vendors - Agenus Inc. - Bavarian Nordic A/S. - Dendreon Corp. - GlaxoSmithKline plc - Novartis International AG Other Prominent Vendors - AFFiRiS AG. - Argos Therapeutics Inc. - Celldex Therapeutics Inc. - CEL-SCI Corp. - Cytos Biotechnology AG - GlobeImmune Inc. - NewLink Genetics Corp. - NovaRx Corp. - Oncothyreon Inc. - TVAX Biomedical Inc. - TapImmune Inc. - Vical Inc. - Vaccinogen Inc. Market Drivers/Trends/Challenges - Increase in Incidence of Cancer, Infectious Diseases, and Physiological Disorders - Ongoing Development of a Large Number of Therapeutic Vaccines - Stringent Regulations - Adverse Side Effects of Therapeutic Vaccines - Increase in Mergers and Acquisitions Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Pipeline Analysis - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zb45f5/global
Marrone Bio Innovations Hires VP of Technology Development
GlobeNewswire - Wed Mar 26, 8:00AM CDT
Marrone Bio Innovations, Inc. (MBI) (Nasdaq:MBII), a leading global provider of bio-based pest management and plant health products announced it has hired Amit Vasavada, Ph.D., as Vice President of Technology Development, a newly created position within the company. Dr. Vasavada brings 30 years of experience in industrial bioproducts, fermentation R&D and manufacturing, process engineering, and technology transfer to MBI. His broad commercial background includes positions with General Atomics, Vical Inc., Diversa Corporation, Monsanto (CP Kelco), and Chiron Corp.
3 Stocks Under $10 Moving Higher
at The Street - Fri Mar 21, 5:18AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Why Vical (VICL) Might Be a Diamond in the Rough? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 7:46AM CDT
Vical has seen loss estimates narrowing over the past month and looks well positioned for a solid gain
Vical to Present at the ROTH Capital Partners 26th Annual Growth Stock Conference
GlobeNewswire - Wed Mar 05, 3:06PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Wednesday, March 12, at 8:30 a.m. PDT at the ROTH Capital Partners 26th Annual Growth Stock Conference (Newport Beach, California March 9 - 12). A webcast of the company's presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.
Vical to Present at the 34th Annual Cowen Health Care Conference
GlobeNewswire - Wed Feb 26, 3:09PM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Monday, March 3, at 2:10 p.m. ET at the 34 Annual Cowen Health Care Conference (Boston, Massachusetts March 3 - 5).
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Hot Stock: Vical, Shares Gain 14.7% (VICL)
Comtex SmarTrend(R) - Wed Feb 12, 10:11AM CST
Vical (NASDAQ:VICL) is one of today's best performing low-priced stocks, up 14.7% to $1.56 on 1.6x average daily volume. Thus far today, Vical has traded 3.4 million shares, vs. average volume of 2.2 million shares per day. The stock has outperformed the Dow (14.7% to the Dow's -0.2%) and outperformed the S&P 500 (14.7% to the S&P's -0.0%) during today's trading.
Vical Reports 2013 Financial Results and Progress in Key Development Programs
GlobeNewswire - Wed Feb 12, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today reported financial results for the year ended December 31, 2013. The net loss for 2013 was $31.2 million, or $0.36 per share, compared with a net loss of $22.9 million, or $0.27 per share, for 2012. Revenues for 2013 were $7.7 million, compared with revenues of $17.5 million for 2012, reflecting lower payments from Astellas Pharma Inc. under an exclusive worldwide license of ASP0113, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients.
The Global Gene Therapy Industry Has the Potential to Become a Multi-Million Dollar Industry by the End of 2017 Says Latest Offering
M2 - Mon Feb 10, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/j8sfvg/global_gene) has announced the addition of the "Global Gene Therapy Market Analysis" report to their offering. Gene therapy is the treatment of a disease by replacing, altering, or supplementing a gene that is absent or abnormal and whose absence or abnormality is causing the disease. It has evolved as one of the most sought after research objectives for difficult to cure' diseases. The gene therapy market in spite of presenting few marketable products and being nascent in terms of revenue generation holds tremendous growth potential. As per a new estimation carried out in our latest study, the global gene therapy industry has the potential to become a multi-million dollar industry by the end of 2017 as new products, especially those in the advanced stage of clinical studies or with pending approvals, may enter the market to boost the growth. According to the new research report, Global Gene Therapy Market Analysis, major focus has been made on the ongoing clinical trials for the development of innovative products. Majority trials are focused on oncology and they prove promising on global scale for US. In this context, the study provides a comprehensive overview of the various aspects of clinical trials in the gene therapy market such as phases, geographies, vector types etc. The report provides an in-depth and prudent analysis of the industry and research developments taking place at the global level. Primarily the market is presently dominated by oncology applications with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeing developments on gene therapy include cardiac conditions, genetic disorders and neurological diseases. An effective analysis of the key therapeutic areas has been included in the report. Companies Mentioned: - AnGes MG, Inc - Ark Therapeutics - Ceregene, Inc - Cobra Biologics - GenVec, Inc - Genzyme Corporation - Vical, Inc - Oxford BioMedica For more information visit http://www.researchandmarkets.com/research/j8...lobal_gene About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Vical to Present at the 2014 Leerink Global Healthcare Conference
GlobeNewswire - Fri Feb 07, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on Thursday, February 13, at 3:30 p.m. ET at the 2014 Leerink Global Healthcare Conference (New York City, February 12 - 13).
Vical Announces News Release and Conference Call Schedule for 2013 Financial Results
GlobeNewswire - Wed Feb 05, 5:30AM CST
Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months and twelve months ended December 31, 2013, before the opening of trading on Wednesday, February 12, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Wednesday, February 12. The call is open on a listen-only basis to any interested parties. The company will provide details on independent and partnered development programs in the conference call and webcast.
Glu Mobile Adds an Arsenal of New Titles to Give â??Deer Hunter' Company: Glu Mobile Inc. (NASDAQ: GLUU), Aeterna Zentaris Inc. (NASDAQ: AEZS), Vical Inc. (NASDAQ:VICL), Delcath Systems Inc. (NASDAQ: DCTH)
ACCESSWIRE - Tue Jan 28, 10:04AM CST
When smartphones meet free-to-play games it creates a business model that game maker Glu Mobile Inc. (NASDAQ: GLUU) is exploiting to the hilt.
